• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects.细胞寿命和细胞传输模型描述促红细胞生成药物作用的比较性能。
AAPS J. 2011 Dec;13(4):650-61. doi: 10.1208/s12248-011-9302-9. Epub 2011 Oct 18.
2
Erythropoiesis equivalence, pharmacokinetics and immune response following repeat hematide administration in cynomolgus monkeys.在食蟹猴中重复给予促红细胞生成素类似物后的红细胞生成等效性、药代动力学和免疫应答。
Int J Immunopathol Pharmacol. 2010 Jan-Mar;23(1):121-9. doi: 10.1177/039463201002300111.
3
Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys.重组人促红细胞生成素在食蟹猴静脉和皮下给药后的药代动力学和药效学建模。
J Pharmacol Exp Ther. 2003 Jul;306(1):324-31. doi: 10.1124/jpet.102.047191. Epub 2003 Apr 3.
4
Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers.健康志愿者中肽类促红细胞生成素受体激动剂(ERA)的群体药代动力学和药效学
J Clin Pharmacol. 2008 Jan;48(1):43-52. doi: 10.1177/0091270007309702. Epub 2007 Nov 19.
5
Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.新型促红细胞生成剂血红素(Hematide)治疗贫血的临床前评估
Exp Hematol. 2006 Oct;34(10):1303-11. doi: 10.1016/j.exphem.2006.05.012.
6
Effects of recombinant human erythropoietin and interleukin-3 on erythropoietic recovery from acute anemia.重组人促红细胞生成素和白细胞介素-3对急性贫血后红细胞生成恢复的影响。
Exp Hematol. 1993 Oct;21(11):1487-91.
7
Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration.猴静脉注射培高利特后清除率、分布、代谢和排泄。
Drug Metab Dispos. 2013 Apr;41(4):774-84. doi: 10.1124/dmd.112.048033. Epub 2013 Jan 14.
8
Population cell life span models for effects of drugs following indirect mechanisms of action.药物通过间接作用机制产生效应的群体细胞寿命模型。
J Pharmacokinet Pharmacodyn. 2005 Dec;32(5-6):767-93. doi: 10.1007/s10928-005-0019-1.
9
Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.用于在药代动力学研究中描述药物吸收的转运室模型的实施。
J Pharmacokinet Pharmacodyn. 2007 Oct;34(5):711-26. doi: 10.1007/s10928-007-9066-0. Epub 2007 Jul 26.
10
Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats.重组人促红细胞生成素在大鼠静脉注射和皮下注射后的药代动力学和药效学建模
J Pharmacol Exp Ther. 2006 Dec;319(3):1297-306. doi: 10.1124/jpet.106.111377. Epub 2006 Sep 14.

引用本文的文献

1
Lifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeutics.基于寿命的抗癌治疗药物抑制肿瘤生长的药代动力学-药效学模型。
PLoS One. 2014 Oct 21;9(10):e109747. doi: 10.1371/journal.pone.0109747. eCollection 2014.
2
Computational approaches to analyse and predict small molecule transport and distribution at cellular and subcellular levels.计算方法分析和预测小分子在细胞和亚细胞水平的转运和分布。
Biopharm Drug Dispos. 2014 Jan;35(1):15-32. doi: 10.1002/bdd.1879. Epub 2013 Dec 10.
3
Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.促红细胞生成素刺激剂的临床药代动力学和药效学。
Clin Pharmacokinet. 2013 Dec;52(12):1063-83. doi: 10.1007/s40262-013-0098-x.
4
Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.治疗性肽的药代动力学和药代动力学-药效学相关性。
Clin Pharmacokinet. 2013 Oct;52(10):855-68. doi: 10.1007/s40262-013-0079-0.
5
General relationship between transit compartments and lifespan models.一般转移隔室与寿命模型之间的关系。
J Pharmacokinet Pharmacodyn. 2012 Aug;39(4):343-55. doi: 10.1007/s10928-012-9254-4. Epub 2012 Jun 23.
6
Lifespan based indirect response models.基于寿命的间接反应模型。
J Pharmacokinet Pharmacodyn. 2012 Feb;39(1):109-23. doi: 10.1007/s10928-011-9236-y. Epub 2012 Jan 3.

本文引用的文献

1
Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models.将转运室药效动力学模型解释为基于寿命的间接反应模型。
J Pharmacokinet Pharmacodyn. 2011 Apr;38(2):179-204. doi: 10.1007/s10928-010-9183-z. Epub 2010 Nov 24.
2
Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.药效学介导的药物处置(PDMDD)和单次罗米司亭在健康受试者中的前体池寿命模型。
AAPS J. 2010 Dec;12(4):729-40. doi: 10.1208/s12248-010-9234-9. Epub 2010 Oct 21.
3
A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes.胰岛素抵抗患者和 2 型糖尿病患者的葡萄糖、胰岛素和β细胞动力学模型。
J Clin Pharmacol. 2010 Aug;50(8):861-72. doi: 10.1177/0091270009349711. Epub 2010 May 19.
4
A semi-physiological-based pharmacokinetic/pharmacodynamic model to describe the effects of topotecan on b-lymphocyte lineage cells.建立半生理药代动力学/药效动力学模型描述拓扑替康对 B 淋巴细胞系细胞的作用。
Pharm Res. 2010 Mar;27(3):431-41. doi: 10.1007/s11095-009-0025-x. Epub 2010 Jan 26.
5
Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems.两种药效传递模型在模型系统中分析肿瘤治疗反应的比较。
AAPS J. 2010 Mar;12(1):1-10. doi: 10.1208/s12248-009-9155-7. Epub 2009 Nov 10.
6
Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects.健康受试者单次静脉给药后聚乙二醇化血小板生成素模拟肽(PEG-TPOm)的药代动力学和药效学建模
J Clin Pharmacol. 2009 Mar;49(3):336-50. doi: 10.1177/0091270008329559.
7
Erythropoietins: a common mechanism of action.促红细胞生成素:一种共同的作用机制。
Exp Hematol. 2008 Dec;36(12):1573-84. doi: 10.1016/j.exphem.2008.08.003. Epub 2008 Oct 14.
8
Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.改变天然细胞寿命分布的药物的基本药效学模型。
J Pharmacokinet Pharmacodyn. 2008 Jun;35(3):349-77. doi: 10.1007/s10928-008-9092-6. Epub 2008 Jun 13.
9
Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects.重组人促红细胞生成素对健康受试者网织红细胞生成率及年龄分布影响的药效学分析
Clin Pharmacokinet. 2008;47(6):399-415. doi: 10.2165/00003088-200847060-00004.
10
Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment.替格列净治疗后2型糖尿病患者血浆葡萄糖、糖化血红蛋白和血红蛋白相互关系的模型
Clin Pharmacol Ther. 2008 Aug;84(2):228-35. doi: 10.1038/clpt.2008.2. Epub 2008 Mar 19.

细胞寿命和细胞传输模型描述促红细胞生成药物作用的比较性能。

Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects.

机构信息

Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, USA.

出版信息

AAPS J. 2011 Dec;13(4):650-61. doi: 10.1208/s12248-011-9302-9. Epub 2011 Oct 18.

DOI:10.1208/s12248-011-9302-9
PMID:22005901
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3231865/
Abstract

Prolonged time delay in response to drug action is a common feature of hematological responses to pharmacotherapy such as erythropoiesis. The objective of this study was to compare the performance of two competing modeling approaches for delayed drug effects, mechanistic cell life span models, and semi-mechanistic cell transit models. The comparison was performed with an experimental dataset from multiple dose administrations of an erythropoietin mimetic to Cynomolgus monkeys. Comparative performance measures include visual predictive checks, goodness-of-fit plots, model estimation time, estimation status, and estimation error. The analysis revealed that both models resulted in a similarly good description of the erythropoietic drug effect, with precision and bias of the model-based predictions of red blood cell counts of less than 11%. The cell transit model needed slightly longer time to converge compared to the cell life span model. The system and drug effect parameters were similar in both models indicating that the models can be interchangeably used to describe the current data. Thus, model selection would be dependent on the purpose of the modeling exercise, the available data, and the time allocated for model development.

摘要

药物作用的响应时间延长是血液学药物治疗(如红细胞生成)反应的一个常见特征。本研究的目的是比较两种竞争性的延迟药物效应建模方法的性能,即基于机制的细胞寿命模型和半机制的细胞传输模型。比较是使用来自多个剂量给予促红细胞生成素类似物给食蟹猴的实验数据集进行的。比较性能指标包括视觉预测检查、拟合优度图、模型估计时间、估计状态和估计误差。分析表明,两种模型都对红细胞生成药物效应进行了类似良好的描述,红细胞计数的模型预测的精度和偏差小于 11%。与细胞寿命模型相比,细胞传输模型需要更长的时间才能收敛。两种模型中的系统和药物效应参数相似,表明这两种模型可以互换使用来描述当前的数据。因此,模型选择将取决于建模练习的目的、可用数据以及为模型开发分配的时间。